Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

NCT03296696 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped Amgen business decision

Conditions

Glioblastoma or Malignant Glioma

Interventions

DRUG: AMG 596
DRUG: AMG 404

Sponsor

Amgen